• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Neuropathol Exp Neurol . Neuropathological features of SARS-CoV-2 delta and omicron variants

tetano

Editor, Senior Moderator
J Neuropathol Exp Neurol


. 2023 Feb 27;nlad015.
doi: 10.1093/jnen/nlad015. Online ahead of print.
Neuropathological features of SARS-CoV-2 delta and omicron variants


Erica Normandin[SUP] 1 [/SUP], Navid Valizadeh[SUP] 2 [/SUP], Emily A Rudmann[SUP] 2 [/SUP], Rockib Uddin[SUP] 3 [/SUP], Sabrina T Dobbins[SUP] 1 [/SUP], Bronwyn L MacInnis[SUP] 1 [/SUP], Robert F Padera[SUP] 4 [/SUP], Katherine J Siddle[SUP] 1 [/SUP], Jacob E Lemieux[SUP] 3 [/SUP], Pardis C Sabeti[SUP] 1 [/SUP], Shibani S Mukerji[SUP] 2 [/SUP], Isaac H Solomon[SUP] 4 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continually evolving resulting in variants with increased transmissibility, more severe disease, reduced effectiveness of treatments or vaccines, or diagnostic detection failure. The SARS-CoV-2 Delta variant (B.1.617.2 and AY lineages) was the dominant circulating strain in the United States from July to mid-December 2021, followed by the Omicron variant (B.1.1.529 and BA lineages). Coronavirus disease 2019 (COVID-19) has been associated with neurological sequelae including loss of taste/smell, headache, encephalopathy, and stroke, yet little is known about the impact of viral strain on neuropathogenesis. Detailed postmortem brain evaluations were performed for 22 patients from Massachusetts, including 12 who died following infection with Delta variant and 5 with Omicron variant, compared to 5 patients who died earlier in the pandemic. Diffuse hypoxic injury, occasional microinfarcts and hemorrhage, perivascular fibrinogen, and rare lymphocytes were observed across the 3 groups. SARS-CoV-2 protein and RNA were not detected in any brain samples by immunohistochemistry, in situ hybridization, or real-time quantitative PCR. These results, although preliminary, demonstrate that, among a subset of severely ill patients, similar neuropathological features are present in Delta, Omicron, and non-Delta/non-Omicron variant patients, suggesting that SARS-CoV-2 variants are likely to affect the brain by common neuropathogenic mechanisms.

Keywords: COVID-19; Delta; Neuropathology; Omicron; SARS-CoV-2.
 
Back
Top Bottom